Given the similar pathophysiological consequences in myocardial ischemia-reperfusion injury and AIS, it is plausible that ARG1 inhibition may represent a promising potential immune modulating treatment following AIS. This evidence concerns the gene ARG1 and androgen insensitivity syndrome.